SCHEMBL5118736

SCHEMBL5118736

O=C(c1ccc(Cl)o1)N1CCC(O)(C#Cc2cccc(Cl)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 2/20 0.46
GRM5 P41594 6/20 0.43
PRSS1 P07477 2/20 0.40
PRSS2 P07478 2/20 0.40
PRSS3 P35030 2/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ENPP2 Q13822 1/20 0.39
ATXN2 Q99700 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
HTR3A P46098 1/20 0.39
PDE4B Q07343 1/20 0.39
USP2 O75604 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126023 0.91 PTPN11 (0.45) PTPN11GRM5PRSS1PRSS2PRSS3
SCHEMBL5115507 0.86 SCN5A (0.54) PTPN11GRM5PRSS1PRSS2PRSS3
SCHEMBL5130079 0.84 ALDH1A1 (0.59) GRM5HPGDSMN1; SMN2LMNAALDH1A1
SCHEMBL5119724 0.83 MAPT (0.54) HPGDSMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL5116452 0.83 GRM5 (0.44) PTPN11GRM5HPGDSMN1; SMN2LMNA
SCHEMBL5129768 0.82 GRM5 (0.54) GRM5ALDH1A1ENPP2ATXN2
SCHEMBL5129480 0.82 GRM5 (0.48) PTPN11GRM5HPGDSMN1; SMN2LMNA
SCHEMBL5115603 0.80 MGLL (0.51) GRM5HPGDSMN1; SMN2LMNAHTT
SCHEMBL5125577 0.80 PKM (0.47) GRM5HPGDSMN1; SMN2LMNAHTT
SCHEMBL5123091 0.79 GRM5 (0.43) GRM5HPGDSMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists NOVARTIS AG (CH) 2008-10-30 US disclosed
EP-1856107-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS Novartis AG (CH) 2007-11-21 EP disclosed
WO-2006089700-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS NOVARTIS AG (CH) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists GRM5, GRIK5, GRM1 PTPN11 3521/4885GRM5 1/4885PRSS1 3850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.